Page last updated: 2024-12-10

epoprostenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5282411
CHEMBL ID1139
CHEBI ID15552
SCHEMBL ID8041
MeSH IDM0017816

Synonyms (78)

Synonym
BIDD:GT0514
BRD-K64054020-001-02-7
gtpl1915
(5z)-5-[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acid
prostaglandin x
pgx ,
vasocyclin
(5z,9alpha,11alpha,13e,15s)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
CHEBI:15552 ,
(5z,13e,15s)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
flolan
(5z,9alpha,11alpha,13e,15s)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
prostaglandin i(2)
6,9-alpha-epoxy-11-alpha,15(s)-dihydroxyprosta-5(z),13(e)-dien-1-oic acid
epoprostenol [usan:inn]
u 53,217
(z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
pgi(sub 2)
prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5z,9alpha,11alpha,13e,15s)-
epoprostanol
kb-iv-24
epoprostenolum [inn-latin]
brn 1690090
SMP2_000227
6,9s-epoxy-11r,15s-dihydoxy-5z,13e-prostadienoic acid
LMFA03010087
IDI1_033966
BSPBIO_001496
prostacyclin
pgi2
prostacyclin i2
DB01240
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
HMS1989K18
pg-i2
u-53217
u-53,217
act-385781a
CHEMBL1139
HMS1791K18
(5z)-5-[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
prosta-5,13-dien-1-oicacid, 6,9-epoxy-11,15-dihydroxy-, (5z,9a,11a,13e,15s)-
unii-dcr9z582x0
u 53217
dcr9z582x0 ,
epoprostenolum
ventaprost
epoprostenol [mart.]
prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5z,9.alpha.,11.alpha.,13e,15s)-
epoprostenol [who-dd]
epoprostenol [vandf]
prostacyclin [mi]
epoprostenol [inn]
epoprostenol [usan]
(z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-.delta.(sup 2,.delta.)-valerate
SCHEMBL8041
63859-31-4
prostaglandin 12
6,9.alpha.-epoxy-11.alpha.,15s-dihydroxyprosta-5z,13e-dien-1-oic acid, monosodium salt
(z)-5-((3ar,4r,5r,6as)-5-hydroxy-4-((s,e)-3-hydroxyoct-1-en-1-yl)hexahydro-2h-cyclopenta[b]furan-2-ylidene)pentanoic acid
HMS3402K18
DTXSID5022988 ,
Q412050
(z)-5-((3ar,4r,5r,6as)-5-hydroxy-4-((s,e)-3-hydroxyoct-1-enyl)hexahydro-2h-cyclopenta[b]furan-2-ylidene)pentanoic acid
(5z)-5-[(3ar,4r,5r,6ar)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(2z,3ar,4r,5r,6as)-5-hydroxy-4-[(1e,3s)-3-hydroxyoct-1-en-1-yl]-hexahydro-2h-cyclopenta[b]furan-2-ylidene]pentanoic acid
EN300-21690431
HY-A0126
CS-0017443
dtxcid602988
(z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-delta(sup 2,delta)-valerate
b01ac09
epoprostenol (mart.)
epoprostenolum (inn-latin)
epoprostenolo
AKOS040744695

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins I
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (70)

PathwayProteinsCompounds
Hemostasis23944
Platelet homeostasis1827
Prostacyclin signalling through prostacyclin receptor14
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Nicotinate metabolism2243
Nicotinamide salvaging1030
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Eicosanoids215
Signaling Pathways1269117
Signaling by GPCR24955
GPCR ligand binding19339
Class A/1 (Rhodopsin-like receptors)16136
Eicosanoid ligand-binding receptors117
Prostanoid ligand receptors75
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin87
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Blood clotting and drug effects05
Eicosanoid metabolism via cyclooxygenases (COX)137
Prostaglandin and leukotriene metabolism in senescence619
Arachidonic acid (AA, ARA) oxylipin metabolism076
Vascular smooth muscle contraction013
Eicosanoid synthesis026
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.06700.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID222762In vitro inhibition of 5.86 uM ADP-induced human platelet aggregation in platelet rich plasma (PRP)1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID228182In vitro hypotensive activity in anesthetized rats after intraperitoneal administration.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities.
AID195433Tested for effect to cause relaxation of renal mesenteric artery previously contracted by PGF2-alpha1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
10,10-Difluoro-13-dehydroprostacyclin: a chemically and metabolically stabilized potent prostacyclin.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID195020In vitro inhibition of ADP (1.25 x 10E-6 M)-induced platelet aggregation in rat PRP (wistar)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID222797Relative activity (compared to acetylsalicylic acid) for in vitro inhibition of collagen-induced human platelet aggregation1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID89295In vitro inhibition of ADP (0.5 x 10E-9 M)-induced platelet aggregation in human PRP1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity.
AID222778In vitro inhibition of collagen-induced human platelet aggregation.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID51039Tested for effect to cause relaxation of bovine coronary artery1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
10,10-Difluoro-13-dehydroprostacyclin: a chemically and metabolically stabilized potent prostacyclin.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID222777In vitro inhibition of ADP-induced human platelet aggregation1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID44748Inhibition of ADP-induced human platelet aggregation.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID24484Compound was evaluated for half life at 37 degree Centigrade1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Biological significance and therapeutic potential of prostacyclin.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346427Human EP4 receptor (Prostanoid receptors)2000British journal of pharmacology, Aug, Volume: 130, Issue:8
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
AID1346350Human IP receptor (Prostanoid receptors)1979The Journal of clinical investigation, Feb, Volume: 63, Issue:2
Selective binding site for [3H]prostacyclin on platelets.
AID1346408Human EP1 receptor (Prostanoid receptors)2002The Journal of pharmacy and pharmacology, Apr, Volume: 54, Issue:4
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (33.33)18.7374
1990's2 (13.33)18.2507
2000's5 (33.33)29.6817
2010's3 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.73 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index122.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension [NCT01370096]Phase 23 participants (Actual)Interventional2012-02-29Terminated(stopped due to Difficulty with patient recruitment)
Prostacyclin Treatment in Severe Traumatic Brain Injury: a Microdialysis and Outcome Study [NCT01363583]Phase 148 participants (Actual)Interventional2002-01-31Completed
Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation [NCT04452669]Phase 211 participants (Actual)Interventional2020-09-15Completed
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study [NCT02251041]Phase 272 participants (Actual)Interventional2014-09-30Completed
TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) [NCT01090037]Phase 2/Phase 3892 participants (Actual)Interventional2010-03-31Completed
An Open-label Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients [NCT00990314]Phase 231 participants (Actual)Interventional2009-11-30Completed
Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism [NCT01014156]Phase 414 participants (Actual)Interventional2004-01-31Completed
A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) [NCT01105091]Phase 430 participants (Actual)Interventional2010-03-31Completed
Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg [NCT01387191]748 participants (Actual)Observational1999-08-31Completed
Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy [NCT01056835]Phase 340 participants (Anticipated)Interventional2009-06-30Completed
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients. [NCT00792571]Phase 218 participants (Actual)Interventional2009-02-28Completed
Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter. [NCT00890214]Phase 423 participants (Actual)Interventional2007-09-30Completed
The Effect of Prostaglandin I2 (Beraprost Na), Administered Orally for Eight Weeks, on the Endothelial Cell Functional Disorder in Type II Diabetes Mellitus Patients With Symptoms of a Minute Peripheral Blood Flow Disorder [NCT01061060]Phase 4110 participants (Actual)Interventional2010-01-31Completed
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study [NCT01886443]Phase 110 participants (Actual)Interventional2013-08-31Completed
A Pilot Study of the Effects of Nebulized Epoprostenol (Flolan) and Systemic Phenylephrine on Arterial Oxygenation During One Lung Ventilation [NCT02748265]Phase 48 participants (Actual)Interventional2016-03-31Completed
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial [NCT05450328]Phase 2141 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2 [NCT00510172]12 participants (Anticipated)Interventional2006-12-31Recruiting
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution [NCT01266265]1,333 participants (Actual)Observational2010-12-31Completed
Trial of Inhaled Alprostadil to Improve Hypoxia and Pulmonary Hypertension [NCT00314548]67 participants (Actual)Interventional2006-05-31Completed
The Effect of Prostacyclin on Haemostasis as Evaluated by Thrombelastography and Endothelial Markers in Patients Undergoing Major Abdominal Surgery. A Pilot Study [NCT01528943]Phase 140 participants (Actual)Interventional2012-03-31Completed
A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to EFI/ACT-385781A in Patients With Pulmonary Arterial Hypertension [NCT01431716]Phase 342 participants (Actual)Interventional2011-03-31Completed
Effect of Prostacyclin Infusion on Cerebral Vessels, Cerebral Bloodflow and Cerebral Metabolism in Patients With Subarachnoid Haemorrhage [NCT01447095]Phase 290 participants (Actual)Interventional2011-10-31Completed
An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) [NCT01105117]Phase 42 participants (Actual)Interventional2010-05-31Completed
Combined Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplantation and for Left Ventricular Assist Device Placement [NCT01717209]Phase 414 participants (Actual)Interventional2012-10-31Completed
[NCT00004754]Phase 40 participants Interventional1993-08-31Completed
A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients [NCT03122730]Phase 215 participants (Actual)Interventional2017-08-23Completed
An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects With Pulmonary Arterial Hypertension (PAH) [NCT02705807]Phase 410 participants (Actual)Interventional2016-05-31Completed
A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.) [NCT01462565]Phase 416 participants (Actual)Interventional2011-11-01Completed
Open-Label, Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Different Formulations of an IP Receptor Agonist [NCT05427162]Phase 1136 participants (Anticipated)Interventional2022-06-21Recruiting
Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension [NCT04231084]Phase 4108 participants (Anticipated)Interventional2021-01-15Recruiting
An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH) [NCT01470144]Phase 341 participants (Actual)Interventional2011-06-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00792571 (6) [back to overview]Change From Baseline in Borg Dyspnea Score at End of Study
NCT00792571 (6) [back to overview]Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at End of Study
NCT00792571 (6) [back to overview]Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
NCT00792571 (6) [back to overview]Number of Treatment Emergent Adverse Events Reported During The Study
NCT00792571 (6) [back to overview]Number of Participants That Experienced Clinical Worsening During the Study
NCT00792571 (6) [back to overview]Number of Participants With a Change in WHO Functional Class
NCT00990314 (5) [back to overview]Change in Borg Dyspnea Score
NCT00990314 (5) [back to overview]Change in Six-Minute-Walk Distance (6MWD)
NCT00990314 (5) [back to overview]Number of Reported Treatment-Emergent Adverse Events
NCT00990314 (5) [back to overview]Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
NCT00990314 (5) [back to overview]Number of Participants That Experienced Clinical Worsening
NCT01105091 (10) [back to overview]Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/Min
NCT01105091 (10) [back to overview]Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/Min
NCT01105091 (10) [back to overview]Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min
NCT01105091 (10) [back to overview]Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/Min
NCT01105091 (10) [back to overview]Blood Pressure - Baseline and Day 28
NCT01105091 (10) [back to overview]Body Weight - Baseline and Day 28
NCT01105091 (10) [back to overview]Heart Rate - Baseline and Day 28
NCT01105091 (10) [back to overview]Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28
NCT01105091 (10) [back to overview]Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28
NCT01105091 (10) [back to overview]Six-minute Walk Distance (6MWD) - Baseline and Day 28
NCT01105117 (2) [back to overview]Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With PAH - Number of Deaths
NCT01105117 (2) [back to overview]Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With Adverse Events Leading Discontinuation of Study Treatment
NCT01266265 (1) [back to overview]Prevalence of Respiratory Tract-Related Adverse Events of Interest
NCT01431716 (14) [back to overview]Change in Borg Dyspnea Score From Baseline to EOT.
NCT01431716 (14) [back to overview]Change in Convenience Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) From Baseline to EOT.
NCT01431716 (14) [back to overview]Change in Effectiveness Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) From Baseline to EOT.
NCT01431716 (14) [back to overview]Change in Global Satisfaction Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) From Baseline to EOT.
NCT01431716 (14) [back to overview]Change in Mean Cardiac Index From Baseline to End of Treatment (EOT).
NCT01431716 (14) [back to overview]Change in Mean Pulmonary Arterial Pressure From Baseline to End of Treatment (EOT).
NCT01431716 (14) [back to overview]Change in Mean Right Atrial Pressure From Baseline to End of Treatment (EOT).
NCT01431716 (14) [back to overview]Change in N-terminal Pro-B-type Natriuretic Peptide (NT proBNP) From Baseline to EOT.
NCT01431716 (14) [back to overview]Change in Pulmonary Capillary Wedge Pressure From Baseline to End of Treatment (EOT).
NCT01431716 (14) [back to overview]Change in Pulmonary Vascular Resistance From Baseline to End of Treatment (EOT).
NCT01431716 (14) [back to overview]Change in Total Pulmonary Resistance From Baseline to End of Treatment (EOT).
NCT01431716 (14) [back to overview]Number of Participants With Improved, No Change, or Worsening of New York Heart Association Functional Class (NYHA FC) From Baseline to EOT.
NCT01431716 (14) [back to overview]Number of Participants With Adverse Events Leading to Discontinuation of Study Drug From Baseline to EOT.
NCT01431716 (14) [back to overview]Change in 6-minute Walk Distance (6MWD) From Baseline to EOT.
NCT01462565 (15) [back to overview]Number of Participants With Abnormal Clinical Chemistry
NCT01462565 (15) [back to overview]Change From Baseline in Vital Signs at Week 4: Heart Rate
NCT01462565 (15) [back to overview]Change From Baseline in Six Minute Walk Distance Test (6MWD) After 4-weeks of Treatment
NCT01462565 (15) [back to overview]Change From Baseline in Dose of Thermo Stable Epoprostenol Sodium at Week 4
NCT01462565 (15) [back to overview]Breathlessness After 6MWD - Borg Dyspnoea Index (BDI)
NCT01462565 (15) [back to overview]Number of Participants With Abnormal Urinalysis
NCT01462565 (15) [back to overview]Number of Participants With Urine Pregnancy Test Positive
NCT01462565 (15) [back to overview]Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)
NCT01462565 (15) [back to overview]Change From Baseline in Study Specific Participant Acceptance Survey
NCT01462565 (15) [back to overview]Change From Baseline in Vital Signs at Week 4 : Systolic and Diastolic Blood Pressure
NCT01462565 (15) [back to overview]Mean Oxygen Saturation in Blood Over Time
NCT01462565 (15) [back to overview]Number of Participants With Abnormal Hematology
NCT01462565 (15) [back to overview]Number of Participants With Any Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events(SAEs)
NCT01462565 (15) [back to overview]Number of Participants With Infusion Site Reactions During Treatment Period
NCT01462565 (15) [back to overview]World Health Organization [WHO] Functional Class at Baseline and After 4- Weeks of Treatment
NCT01470144 (2) [back to overview]Treatment-emergent Adverse Events
NCT01470144 (2) [back to overview]Exposure Duration
NCT01717209 (6) [back to overview]Right Heart Dysfunction
NCT01717209 (6) [back to overview]Systemic Vascular Resistance (SVR)
NCT01717209 (6) [back to overview]Pulmonary Hypertension
NCT01717209 (6) [back to overview]Mean Arterial Pressure (MAP)
NCT01717209 (6) [back to overview]Heart Rate
NCT01717209 (6) [back to overview]Central Venous Pressure (CVP)
NCT02705807 (27) [back to overview]Change From Baseline in Pulmonary Vascular Resist (PVR)
NCT02705807 (27) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT02705807 (27) [back to overview]Number of Events to Adjust Dose of FLOLAN Based on the Change From Baseline to 3 Hours in Mean Pulmonary Artery Pressure (mPAP)
NCT02705807 (27) [back to overview]Number of Participants in Each World Health Organization (WHO) Functional Class
NCT02705807 (27) [back to overview]Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT02705807 (27) [back to overview]Number of Participants With Mild, Moderate or Severe AEs
NCT02705807 (27) [back to overview]Number of Participants With the Indicated Electrocardiogram (ECG) Findings
NCT02705807 (27) [back to overview]Number of Participants With the Indicated Urinalysis Findings
NCT02705807 (27) [back to overview]Number of Participants With the Reason for the Change Dose of the Thermostable Formulation of FLOLAN
NCT02705807 (27) [back to overview]Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils in Blood at Baseline and Week 4
NCT02705807 (27) [back to overview]Change From Baseline in Body Weight
NCT02705807 (27) [back to overview]Change From Baseline in Cardiac Output (CO)
NCT02705807 (27) [back to overview]Change From Baseline in Heart Rate
NCT02705807 (27) [back to overview]Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) and Mean Right Atrial Pressure (mRAP)
NCT02705807 (27) [back to overview]Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT Pro BNP)
NCT02705807 (27) [back to overview]Absolute Values of Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Gamma Glutamyltransferase, Lactate Dehydrogenase and Creatine Kinase at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Albumin and Total Protein at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Free Triiodothyronine and Free Thyroxine at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Hematocrit at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Hemoglobin at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Oxygen Saturation
NCT02705807 (27) [back to overview]Absolute Values of Platelet Count and White Blood Cell Count at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Red Blood Cell Count at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Thyroid Stimulating Hormone at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Total and Direct Bilirubin, Creatinine, and Uric Acid at Baseline and Week 4
NCT02705807 (27) [back to overview]Absolute Values of Urea/Blood Urea Nitrogen, Glucose, Chloride, Sodium, Potassium, Magnesium, Phosphorus (Inorganic), and Calcium at Baseline and Week 4
NCT02705807 (27) [back to overview]Number of Participants With Change of WHO Functional Class From Previous Visit

Change From Baseline in Borg Dyspnea Score at End of Study

The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Baseline was defined as the last non-missing evaluation preceding the first dose of study drug in study BPS-MR-PAH-201. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00792571)
Timeframe: Baseline and 56 months

Interventionscores on a scale (Mean)
Beraprost Sodium-0.09

[back to top]

Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at End of Study

"The area used for the Six Minute Walk Test (6MWT) was pre-measured at a minimum of 30 meters in length and at least 2 to 3 meters in width. There were no turns or significant curves to the 6-minute walk area. The length was marked with gradations to ensure the accurate measurement of the distance walked. The area was well ventilated with air temperature controlled at 20 to 23°C. Intermittent rest periods were allowed if the participant could no longer continue. If the participant needed to rest briefly, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called stop while simultaneously stopping the watch and then measured the distance walked. For the purposes of the 6MWT if a participant was assessed at Baseline using oxygen therapy, then all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted." (NCT00792571)
Timeframe: Baseline and 56 months

Interventionmeters (Mean)
Beraprost Sodium10.55

[back to top]

Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE)

A treatment-emergent adverse event (TEAEs) is defined as an event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments. AEs occurring more than 3 days after the last day study drug is taken in the study will not be included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only treatment-emergent adverse events occurring during the treatment period of the BPS-MR-PAH-202 study will be summarized. Any adverse event starting prior to the first dose of study drug will be excluded from the summary analyses and only presented in the data listings. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00792571)
Timeframe: Up to 56 months

InterventionParticipants (Count of Participants)
Beraprost Sodium18

[back to top]

Number of Treatment Emergent Adverse Events Reported During The Study

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for participants with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-202 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00792571)
Timeframe: Up to 56 months

InterventionTEAEs (Number)
Beraprost Sodium156

[back to top]

Number of Participants That Experienced Clinical Worsening During the Study

Number of Participants that experienced Clinical Worsening in the opinion of the Investigator. Clinical Worsening was defined as any of these events following the Baseline visit: Death, Transplantation or atrial septostomy, Clinical deterioration as defined by: Hospitalization as a result of PAH symptoms or Initiation of any new PAH specific therapy (e.g. ERA, PDE-5 inhibitor, prostanoid). All efficacy results are descriptive; no statistical analysis was conducted. (NCT00792571)
Timeframe: Up to 56 months

InterventionParticipants (Count of Participants)
DeathNew PAH TherapiesTransplantation or atrial septostomyHospitalization
Beraprost Sodium1600

[back to top]

Number of Participants With a Change in WHO Functional Class

Change from Baseline in participant clinical status was recorded according to the World Health Organization (WHO) Functional Class. A change from lower to higher functional class (i.e. 'III to IV' or 'II to III') was considered as a deterioration. A change from higher to lower functional class (i.e. 'III to II' or 'II to I') was considered as an improvement. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00792571)
Timeframe: Baseline and 56 months

InterventionParticipants (Number)
Improved: Change from Class III to Class IINo Change in ClassDeteriorated: Change from Class II to Class IIINot Reported
Beraprost Sodium1746

[back to top]

Change in Borg Dyspnea Score

The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Baseline was defined as the last non-missing evaluation preceding the first dose of study drug in study BPS-MR-PAH-203. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00990314)
Timeframe: Baseline and 42 months

Interventionscores on a scale (Mean)
Beraprost Sodium0.86

[back to top]

Change in Six-Minute-Walk Distance (6MWD)

"Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called stop while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted." (NCT00990314)
Timeframe: Baseline and 42 months

Interventionmeters (Mean)
Beraprost Sodium24.09

[back to top]

Number of Reported Treatment-Emergent Adverse Events

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-204 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00990314)
Timeframe: Up to 42 months

InterventionTEAEs (Number)
Beraprost Sodium230

[back to top]

Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-204 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted (NCT00990314)
Timeframe: Up to 42 months

InterventionParticipants (Count of Participants)
Beraprost Sodium27

[back to top]

Number of Participants That Experienced Clinical Worsening

Number of Participants that experienced Clinical Worsening in the opinion of the Investigator. Clinical Worsening was defined as any of these events following the Baseline visit: Death, Transplantation or atrial septostomy, Clinical deterioration as defined by: Hospitalization as a result of PAH symptoms or Initiation of any new PAH specific therapy (e.g. ERA, PDE-5 inhibitor, prostanoid). All efficacy results are descriptive; no statistical analysis was conducted. (NCT00990314)
Timeframe: Up to 42 months

InterventionParticipants (Count of Participants)
DeathHospitalization As A Result of PAH SymptomsNew PAH TherapiesTransplantation or atrial septostomy
Beraprost Sodium1240

[back to top]

Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/Min

The plasma concentration for the epoprostenol metabolite 6-keto-Prostacyclin F1alpha was measured at 2 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results. (NCT01105091)
Timeframe: Day 1

Intervention(pg/ml)/(ng/kg/min) (Median)
ACT-385781A (Epoprostenol for Injection)85.5
Flolan® (Epoprostenol Sodium) for Injection109.2

[back to top]

Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/Min

The plasma concentration for the epoprostenol metabolite 6-keto-Prostacyclin F1alpha was measured at 4 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results. (NCT01105091)
Timeframe: Day 1

Intervention(pg/ml)/(ng/kg/min) (Median)
ACT-385781A (Epoprostenol for Injection)93.1
Flolan® (Epoprostenol Sodium) for Injection95.0

[back to top]

Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min

The plasma concentration for the epoprostenol metabolite 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha was measured at 2 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results. (NCT01105091)
Timeframe: Day 1

Intervention(pg/ml)/(ng/kg/min) (Median)
ACT-385781A (Epoprostenol for Injection)98.0
Flolan® (Epoprostenol Sodium) for Injection83.1

[back to top]

Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/Min

The plasma concentration for the epoprostenol metabolite 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha was measured at 4 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results. (NCT01105091)
Timeframe: Day 1

Intervention(pg/ml)/(ng/kg/min) (Median)
ACT-385781A (Epoprostenol for Injection)90.9
Flolan® (Epoprostenol Sodium) for Injection59.6

[back to top]

Blood Pressure - Baseline and Day 28

Blood pressure (systolic and diastolic) were measured indirectly using an automatic oscillometric device, on the same arm for each measurement. The Blood Pressure was assessed at baseline and at Day 28 (End of Study Treatment visit). (NCT01105091)
Timeframe: Baseline and 28 days

,
Interventionmm Hg (Median)
Systolic Blood Pressure (Baseline)Systolic Blood Pressure (Day 28)Diastolic Blood Pressure (Baseline)Diastolic Blood Pressure (Day 28))
ACT-385781A (Epoprostenol for Injection)106.5117.562.071.0
Flolan® (Epoprostenol Sodium) for Injection106.5116.068.073.0

[back to top]

Body Weight - Baseline and Day 28

Body weight was measured both at baseline and day 28. (NCT01105091)
Timeframe: Baseline and 28 days

,
Interventionkg (Median)
BaselineDay 28
ACT-385781A (Epoprostenol for Injection)74.173.6
Flolan® (Epoprostenol Sodium) for Injection74.273.3

[back to top]

Heart Rate - Baseline and Day 28

Heart rate was measured indirectly using an automatic oscillometric device, on the same arm for each measurement. The Heart Rate was assessed at Baseline and at Day 28 (End of Study Treatment visit). (NCT01105091)
Timeframe: Baseline and 28 days

,
InterventionBeats per minute (Median)
BaselineDay 28
ACT-385781A (Epoprostenol for Injection)83.085.0
Flolan® (Epoprostenol Sodium) for Injection77.588.0

[back to top]

Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28

Disease severity was assessed by NYHA classification of PAH criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA. (NCT01105091)
Timeframe: From baseline to 28 days (+3 days)

,
Interventionparticipants (Number)
Improved PatientsWorsened Patients
ACT-385781A (Epoprostenol for Injection)60
Flolan® (Epoprostenol Sodium) for Injection30

[back to top]

Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28

Central venous blood oxygen saturation assessment was performed only in specific centers. Measurements for ScVO2 were performed during the inpatient hospitalization period on Day 1 (prior to drug initiation) and on Day 28 (EOT). Samples for ScVO2 were obtained by aspirating blood from the indwelling central venous catheter. After the sample had been drawn, the catheter was primed with study drug in order to refill the lumen to avoid interruption in treatment and sudden decompensation. (NCT01105091)
Timeframe: Baseline and 28 days

,
Interventionpercentage oxygen saturation (Median)
BaselineDay 28
ACT-385781A (Epoprostenol for Injection)63.058.0
Flolan® (Epoprostenol Sodium) for Injection61.556.0

[back to top]

Six-minute Walk Distance (6MWD) - Baseline and Day 28

The 6-minute walk test (6MWT) was to be performed prior to initiating study treatment either during the screening visit or on Day 1 prior to drug initiation, and Day 28 (End of treatment (EOT)). This assessment is a non-encouraged test that measures the distance walked for a duration of 6 minutes. The 6MWD was recorded in the Case Report Form (CRF). (NCT01105091)
Timeframe: Baseline and 28 days (+3 days)

,
Interventionmeters (Median)
BaselineDay 28
ACT-385781A (Epoprostenol for Injection)339.0288.0
Flolan (Epoprostenol Sodium) for Injection302.5323.5

[back to top]

Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With PAH - Number of Deaths

(NCT01105117)
Timeframe: Up to 39 days. Day 1 - until patients transition from study medication to commercially-obtained medication

Interventionparticipants (Number)
ACT-385781A (Epoprostenol for Injection)0
Flolan® (Epoprostenol Sodium) for Injection0

[back to top]

Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With Adverse Events Leading Discontinuation of Study Treatment

(NCT01105117)
Timeframe: Up to 39 days. Day 1 - until patients transition from study medication to commercially-obtained medication

Interventionparticipants (Number)
ACT-385781A (Epoprostenol for Injection)0
Flolan® (Epoprostenol Sodium) for Injection0

[back to top] [back to top]

Change in Borg Dyspnea Score From Baseline to EOT.

"The Borg dyspnea score was assessed at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. The Borg scale is a category-ratio scale, commonly used to evaluate the effects of exercise on dyspnea. The original and modified scales have ratio properties ranging from 0 = nothing at all to 10 = very, very severe, with descriptors from 0 to 10. Descriptors have been modified by others so that 10 has been labelled extremely severe, or the worst possible dyspnea imaginable." (NCT01431716)
Timeframe: Approximately 3 months

Interventionunits on a scale (Mean)
BaselineEnd of treatment
EFI/ACT-385781A4.03.3

[back to top]

Change in Convenience Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) From Baseline to EOT.

Patients were required to complete the TSQM-9 questionnaire at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. The TSQM-9 is a validated instrument to assess patients' satisfaction with medication, including a three question convenience scale. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. (NCT01431716)
Timeframe: Approximately 3 months

Interventionunits on a scale (Mean)
BaselineEnd of treatment
EFI/ACT-385781A53.6566.37

[back to top]

Change in Effectiveness Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) From Baseline to EOT.

Patients were required to complete the TSQM-9 questionnaire at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. The TSQM-9 is a validated instrument to assess patients' satisfaction with medication, including a three question effectiveness scale. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. (NCT01431716)
Timeframe: Approximately 3 months

Interventionunits on a scale (Mean)
BaselineEnd of treatment
EFI/ACT-385781A78.2274.71

[back to top]

Change in Global Satisfaction Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) From Baseline to EOT.

Patients were required to complete the TSQM-9 questionnaire at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. The TSQM-9 is a validated instrument to assess patients' satisfaction with medication, including a three question global satisfaction scale. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. (NCT01431716)
Timeframe: Approximately 3 months

Interventionunits on a scale (Mean)
BaselineEnd of treatment
EFI/ACT-385781A71.8275.22

[back to top]

Change in Mean Cardiac Index From Baseline to End of Treatment (EOT).

Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

InterventionL/min/m^2 (Mean)
BaselineEnd of treatment
EFI/ACT-385781A3.343.38

[back to top]

Change in Mean Pulmonary Arterial Pressure From Baseline to End of Treatment (EOT).

Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

InterventionmmHg (Mean)
BaselineEnd of treatment
EFI/ACT-385781A51.951.7

[back to top]

Change in Mean Right Atrial Pressure From Baseline to End of Treatment (EOT).

Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

InterventionmmHg (Mean)
BaselineEnd of treatment
EFI/ACT-385781A7.97.1

[back to top]

Change in N-terminal Pro-B-type Natriuretic Peptide (NT proBNP) From Baseline to EOT.

Blood sampling for NT proBNP was performed at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

Interventionng/L (Mean)
BaselineEnd of treatment
EFI/ACT-385781A599.97613.56

[back to top]

Change in Pulmonary Capillary Wedge Pressure From Baseline to End of Treatment (EOT).

Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

InterventionmmHg (Mean)
BaselineEnd of treatment
EFI/ACT-385781A10.310.1

[back to top]

Change in Pulmonary Vascular Resistance From Baseline to End of Treatment (EOT).

Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

Interventiondyn/sec/cm^5 (Mean)
BaselineEnd of treatment
EFI/ACT-385781A595.70587.66

[back to top]

Change in Total Pulmonary Resistance From Baseline to End of Treatment (EOT).

Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. (NCT01431716)
Timeframe: Approximately 3 months

Interventiondyn/sec/cm^5 (Mean)
BaselineEnd of treatment
EFI/ACT-385781A752.44757.51

[back to top]

Number of Participants With Improved, No Change, or Worsening of New York Heart Association Functional Class (NYHA FC) From Baseline to EOT.

NYHA FC was assessed at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. Disease severity was assessed by NYHA classification of pulmonary arterial hypertension criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA. (NCT01431716)
Timeframe: Approximately 3 months

Interventionparticipants (Number)
ImprovedNo changeWorsened
EFI/ACT-385781A1354

[back to top]

Number of Participants With Adverse Events Leading to Discontinuation of Study Drug From Baseline to EOT.

Adverse events that led to discontinuation of study drug from the start of study treatment until the end of study treatment were recorded. (NCT01431716)
Timeframe: Approximately 3 months

Interventionparticipants (Number)
EFI/ACT-385781A0

[back to top]

Change in 6-minute Walk Distance (6MWD) From Baseline to EOT.

The 6MWD was assessed at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT. The 6-minute walk test is a non-encouraged test that measures the distance walked for the duration of 6 min. (NCT01431716)
Timeframe: Approximately 3 months

Interventionm (Mean)
BaselineEnd of treatment
EFI/ACT-385781A498.1492.8

[back to top]

Number of Participants With Abnormal Clinical Chemistry

Abnormal clinical chemistry was analyzed as follows: serum alanine aminotransferase (ALT/SGPT) >= 3 x upper limit of normal (ULN) , aspartate aminotransferase (AST/SGOT) >= 3 x ULN , total bilirubin >= 34.2, creatinine >= 176.8. (NCT01462565)
Timeframe: Up to 1 week after Week 4 (Follow-up)

InterventionParticipants (Count of Participants)
Epoprostenol Sodium for Injection0

[back to top]

Change From Baseline in Vital Signs at Week 4: Heart Rate

Summary mean change in heart rate measured in beats per minute (beats/min or BPM). Change from Baseline was calculated as the value at the indicated time points minus the value at Baseline. Baseline was Visit 2 i.e. Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) to Week 4

Interventionbeats/min (Mean)
Epoprostenol Sodium for Injection-1.7

[back to top]

Change From Baseline in Six Minute Walk Distance Test (6MWD) After 4-weeks of Treatment

This assessment was a non-encouraged test that measures the distance walked for a duration of 6 minutes. Change from Baseline was calculated as value at observation minus value at Baseline. Baseline visit was Visit 2 i.e. Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4

Interventionmeters (Mean)
Epoprostenol Sodium for Injection-3.55

[back to top]

Change From Baseline in Dose of Thermo Stable Epoprostenol Sodium at Week 4

Dose titration requirement was assessed at the time of discharge. Change from Baseline was calculated as score at observation minus score at Baseline. Units- nanogram per kilogram per minute (ng/kg/min). Baseline was Visit 2 i.e . Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4

Interventionng/kg/min (Mean)
Epoprostenol Sodium for Injection0.22

[back to top]

Breathlessness After 6MWD - Borg Dyspnoea Index (BDI)

The BDI was calculated by using a 10-point scale (0 = None, 10 = Maximum) and indicates the degree of breathlessness after completion of the 6-minute walk test. The BDI scale was assessed by each participant. Change from Baseline = score at observation minus score at Baseline. Baseline visit was Visit 2 i.e. Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) to Week 4

InterventionScore on a scale (Mean)
Epoprostenol Sodium for Injection0.36

[back to top]

Number of Participants With Abnormal Urinalysis

Dipstick method was used to measure blood, glucose and protein. Data was analyzed up to 1 week after Week 4 (Follow-up visit). (NCT01462565)
Timeframe: Up to 1 week after Week 4 (Follow-up)

InterventionParticipants (Count of Participants)
Epoprostenol Sodium for Injection0

[back to top]

Number of Participants With Urine Pregnancy Test Positive

Urine samples were collected for urine pregnancy test. Urine samples were collected at up to the treatment follow up (1 week after Visit 3 [Week 4]). Number of participants with urine pregnancy test positive has been reported. (NCT01462565)
Timeframe: up to the treatment follow up (1 week after Visit 3 [Week 4])

InterventionParticipants (Count of Participants)
Epoprostenol Sodium for Injection0

[back to top]

Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores was considered as better health status. Change from Baseline was calculated as score at observation minus score at baseline. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3)

InterventionScore on a scale (Mean)
Physical FunctioningRole-PhysicalRole-EmotionalVitalityMental HealthSocial FunctioningBodily PainGeneral HealthPhysical Health ComponentMental Health Component
Epoprostenol Sodium for Injection-1.156-0.7650.0020.7810.8831.7063.065-0.606-0.1231.141

[back to top]

Change From Baseline in Study Specific Participant Acceptance Survey

Study-specific questionnaire comprised the pre-defined15 questions which included activities of daily living assessment. Participants rated the question on a scale of 1 to 10, where 1 was do not agree and 10 was strongly agree. Change from Baseline was calculated as score at observation minus score at Baseline. Changes from Baseline was assessed for Questions 2 to 12. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3).

InterventionScore on a scale (Mean)
Q2- ability to perform physical activitiesQ3- ability to perform your basic daily activiesQ4- ability to perform activities with your familyQ5- ability to participate in social activitiesQ6- ability to comply with your Flolan treatmentQ7- ability to perform new activity(Jogging, walk)Q8- overall satisfactionQ9- interested physical activityQ10- feel physically restricted from participatingQ11- confident in my ability to do new activityQ12- treatment regimen constantly weighs on mind
Epoprostenol Sodium for Injection-0.9-1.5-0.8-0.90.30.40.4-0.10.10.6-0.6

[back to top]

Change From Baseline in Vital Signs at Week 4 : Systolic and Diastolic Blood Pressure

Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Change from Baseline was calculated as the value at the indicated time points minus the value at Baseline. Baseline was Visit 2 i.e. Day-14 (+ or - 7 days). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4(Visit 3)

InterventionMillimeter of mercury (mmHg) (Mean)
Systolic blood pressureDiastolic blood pressure
Epoprostenol Sodium for Injection-0.40.4

[back to top]

Mean Oxygen Saturation in Blood Over Time

Pulse oximetry (oxygen saturation) was analyzed. Data for Pulse oximetry (oxygen saturation) was analyzed up to the treatment follow up (1 week after Visit 3 [Week 4]). (NCT01462565)
Timeframe: up to the treatment follow up (1 week after Visit 3 [Week 4])

InterventionPercentage of oxygen in blood (Mean)
BaselineWeek 4Follow-up (1 week after Week 4)
Epoprostenol Sodium for Injection94.394.593.0

[back to top]

Number of Participants With Abnormal Hematology

Values for hemoglobin, hematocrit, and platelet count were analyzed. Participants with abnormal values have been reported. The low and high value concern were as follows: hemoglobin (Males < 98, >180.0) (females <91, >161.0)grams per litre (g/L); hematocrit (Males < 32.0, >54.0) (females <29.0, >50.6) fraction (1); platelet count (< 100, > 500) gram international units per litre (gI/L). (NCT01462565)
Timeframe: Up to 1 week after Week 4 (Follow-up)

InterventionParticipants (Count of Participants)
Hemoglobin (G/L) : Week 4: highHematocrit (1): Screening: LowHematocrit (1): Baseline: LowHematocrit (1): Week 4: LowHematocrit (1): Follow-up: LowPlatelet count (GI/L): Screening: LowPlatelet count (GI/L): Baseline: LowPlatelet count (GI/L): Week 4: LowPlatelet count (GI/L): Follow up: Low
Epoprostenol Sodium for Injection114151515211

[back to top]

Number of Participants With Any Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events(SAEs)

An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, congenital anomaly/birth defect and medically significant and all events of possible drug-induced liver injury with hyperbilirubinaemia. Only treatment emergent AEs and SAEs were reported in this outcome measure. Specifically, this study reported 2 SAEs, but only 1 was categorized as treatment emergent. (NCT01462565)
Timeframe: Up to visit 3 (Week 4)

InterventionParticipants (Count of Participants)
Any AEsAny SAEs
Epoprostenol Sodium for Injection91

[back to top]

Number of Participants With Infusion Site Reactions During Treatment Period

Infusion site reactions were reported during the treatment period. Infusion site was inspected for erythema, excoriation, induration, skin necrosis or signs of local sepsis. (NCT01462565)
Timeframe: Baseline visit (Visit 2) to Week 4 (Visit 3)

InterventionParticipants (Count of Participants)
ErythemaSigns of local sepsisOther
Epoprostenol Sodium for Injection111

[back to top]

World Health Organization [WHO] Functional Class at Baseline and After 4- Weeks of Treatment

World Health Organization functional class was analyzed as class I, class II, class III and class IV. World Health Organization functional class was analyzed at Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4. The classed were defined as Class I: No symptoms of pulmonary arterial hypertension with exercise or at rest, Class II: No symptoms at rest but uncomfortable and short of breath with normal activity, Class III: May not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting and Class IV: Symptoms at rest and severe symptoms with any activity. Hence the severity increased from class I (better) to Class IV (worse). (NCT01462565)
Timeframe: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4

InterventionParticipants (Count of Participants)
Baseline WHO Class IBaseline WHO Class IIBaseline WHO Class IIIBaseline WHO Class IVWeek 4 Class IWeek 4 Class IIWeek 4 Class IIIWeek 4 Class IV
Epoprostenol Sodium for Injection294021040

[back to top]

Treatment-emergent Adverse Events

(NCT01470144)
Timeframe: On average 2.72 years

InterventionNumber of patients (Number)
Treatment41

[back to top]

Exposure Duration

Duration of exposure to EFI (NCT01470144)
Timeframe: On average 2.72 years

Interventionyear (Median)
Treatment2.44

[back to top]

Right Heart Dysfunction

Right Heart Dysfunction was measured as mean of Right Ventricular Stroke Work Index (RVSWI) for the initial 8 hours after admission to the Intensive Care Unit (ICU). RVSWI is measured as the difference in mean pulmonary artery pressure (MPAP) and central venous pressure (CVP), divided by the cardiac index (CI): [(MPAP-CVP) / CI]. Normal range for RVSWI is 5-10 g/m. (NCT01717209)
Timeframe: 8 hours (upon arrival at ICU, and after 4 successive 2 hour treatments with 1. iNO only, 2. iNO+iPGI2 (1st), 3. iPGI2 only, and 4. iNO+iPGI2 (2nd))

Interventiong/m (Mean)
At Arrival in ICUFollowing iNOFollowing iNO+iPGI2 (1st)Following iPGI2Following iNO+iPGI2 (2nd)
Combined Nitric Oxide and Prostacyclin5.25.04.85.44.9

[back to top]

Systemic Vascular Resistance (SVR)

Systemic Vascular Resistance (SVR) was measured as mean of Systemic Vascular Resistance (SVR) for the initial 8 hours after admission to the Intensive Care Unit (ICU). Normal range for SVR is 800-1200 dynes/sec/cm5. (NCT01717209)
Timeframe: 8 hours (upon arrival at ICU, and after 4 successive 2 hour treatments with 1. iNO only, 2. iNO+iPGI2 (1st), 3. iPGI2 only, and 4. iNO+iPGI2 (2nd))

Interventiondynes/sec/cm^5 (Mean)
At Arrival in ICUFollowing iNOFollowing iNO+iPGI2 (1st)Following iPGI2Following iNO+iPGI2 (2nd)
Combined Nitric Oxide and Prostacyclin1193.91169.71070.61132.41145.9

[back to top]

Pulmonary Hypertension

Pulmonary hypertension was measured as mean of Mean Pulmonary Artery Pressure for initial 8 hours after admission to the Intensive Care Unit (ICU). MPAP value ≥25 mmHg (resting) indicates pulmonary hypertension state. (NCT01717209)
Timeframe: 8 hours (upon arrival at ICU, and after 4 successive 2 hour treatments with 1. iNO only, 2. iNO+iPGI2 (1st), 3. iPGI2 only, and 4. iNO+iPGI2 (2nd))

InterventionmmHg (Mean)
At Arrival in ICUFollowing iNOFollowing iNO+iPGI2 (1st)Following iPGI2Following iNO+iPGI2 (2nd)
Combined Nitric Oxide and Prostacyclin31.429.125.925.425.4

[back to top]

Mean Arterial Pressure (MAP)

Mean Arterial Pressure (MAP) was measured as mean of MAP for the initial 8 hours after admission to the Intensive Care Unit (ICU). Normal range for MAP is 70-110 mmHg. (NCT01717209)
Timeframe: 8 hours (upon arrival at ICU, and after 4 successive 2 hour treatments with 1. iNO only, 2. iNO+iPGI2 (1st), 3. iPGI2 only, and 4. iNO+iPGI2 (2nd))

InterventionmmHg (Mean)
At Arrival in ICUFollowing iNOFollowing iNO+iPGI2 (1st)Following iPGI2Following iNO+iPGI2 (2nd)
Combined Nitric Oxide and Prostacyclin86.2980.8679.0079.4380.86

[back to top]

Heart Rate

Heart Rate was measured as mean of Heart Rate for the initial 8 hours after admission to the Intensive Care Unit (ICU). Normal range for heart rate is generally 60 to 100 beats per minutes in adults, but this can vary. (NCT01717209)
Timeframe: 8 hours (upon arrival at ICU, and after 4 successive 2 hour treatments with 1. iNO only, 2. iNO+iPGI2 (1st), 3. iPGI2 only, and 4. iNO+iPGI2 (2nd))

Interventionbeats/minute (Mean)
At Arrival in ICUFollowing iNOFollowing iNO+iPGI2 (1st)Following iPGI2Following iNO+iPGI2 (2nd)
Combined Nitric Oxide and Prostacyclin111.1112.5108.4106.0104.6

[back to top]

Central Venous Pressure (CVP)

Central Venous Pressure (CVP) was measured as mean of CVP for the initial 8 hours after admission to the Intensive Care Unit (ICU). Normal range for CVP is 3-8 mmHg. (NCT01717209)
Timeframe: 8 hours (upon arrival at ICU, and after 4 successive 2 hour treatments with 1. iNO only, 2. iNO+iPGI2 (1st), 3. iPGI2 only, and 4. iNO+iPGI2 (2nd))

InterventionmmHg (Mean)
At Arrival in ICUFollowing iNOFollowing iNO+iPGI2 (1st)Following iPGI2Following iNO+iPGI2 (2nd)
Combined Nitric Oxide and Prostacyclin12.712.611.610.110.6

[back to top]

Change From Baseline in Pulmonary Vascular Resist (PVR)

The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Baseline and up to Week 4

Interventionmillimeter mercury/liter/minute (Mean)
1hr3hr24hrWeek 4
FLOLAN With New Diluent0.204-0.0770.1960.368

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured at Baseline, 1 hr, 3 hr, 24 hr, Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Baseline, 1 hour, 3 hour, 24 hour and Week 4

InterventionMillimeters of mercury (mmHg) (Mean)
SBP, 1 hrSBP, 3 hrSBP, 24 hrSBP, Week 4DBP, 1 hrDBP, 3 hrDBP, 24 hrDBP, Week 4
FLOLAN With New Diluent4.21.21.12.1-0.60.70.92.5

[back to top]

Number of Events to Adjust Dose of FLOLAN Based on the Change From Baseline to 3 Hours in Mean Pulmonary Artery Pressure (mPAP)

To assess the frequency of dose adjustment requirements based on the changes from baseline in mPAP up to 3 hours after dosing.The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Participants who gave consent to undergo right heart catheterisation (RHC) over 24-hour and at week 4 were assessed. Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Up to Week 4

InterventionNumber of events (Number)
YesNo
FLOLAN With New Diluent010

[back to top]

Number of Participants in Each World Health Organization (WHO) Functional Class

The WHO functional classes of PAH range from Class I (without limitation in physical activity) to Class IV (inability to perform a physical activity without any symptoms). (NCT02705807)
Timeframe: Baseline and Week 4

InterventionParticipants (Number)
WHO Class I, BLWHO Class II, BLWHO Class III, BLWHO Class IV, BLWHO Class I, W4WHO Class II, W4WHO Class III, W4WHO Class IV, W4
FLOLAN With New Diluent190001000

[back to top]

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical interventions. Intention-to-Treat (ITT) population: comprised of all participants who have received at least one dose of the thermostable formulation of FLOLAN. (NCT02705807)
Timeframe: Up to Week 4

InterventionParticipants (Number)
Any AEAny Drug-Related AEAny SAE
FLOLAN With New Diluent210

[back to top]

Number of Participants With Mild, Moderate or Severe AEs

Intensity for an AE and SAE is categorized as mild if an event is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate if an event is sufficiently discomforting to interfere with normal everyday activities; severe if that prevents normal everyday activities. (NCT02705807)
Timeframe: Up to Week 4

InterventionParticipants (Number)
Mild, NauseaMild, Hepatic function abnormal
FLOLAN With New Diluent11

[back to top]

Number of Participants With the Indicated Electrocardiogram (ECG) Findings

A safety 12-lead ECG was performed at Baseline (BL), 24 hr after switching to the new Flolan diluent and Week 4 (W4). Any abnormal clinically significant (CS) and not clinically significant (NCS) findings were reported. ECG abnormaility with respect to CS and NCS findings were judged by the investigator. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline, 24 hour and Week 4

InterventionParticipants (Number)
BL, NCSBL, CS24 hr, NCS24 hr, CSW4, NCSW4, CS
FLOLAN With New Diluent9191100

[back to top]

Number of Participants With the Indicated Urinalysis Findings

Urine protein, urine glucose, and occult blood were assessed at Baseline (BL) and Week 4 (W4). Dipstick test was performed for routine urinalysis. Abnormal values such as trace, 1+, 2+, 3+ and positive have been reported. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). (NCT02705807)
Timeframe: Baseline and Week 4

InterventionParticipants (Number)
Urine glucose, BL, TraceUrine glucose, BL, 1+Urine glucose, BL, 2+Urine glucose, BL, 3+Urine glucose, BL, PositiveUrine glucose, W4, TraceUrine glucose, W4, 1+Urine glucose, W4, 2+Urine glucose, W4, 3+Urine glucose, W4, PositiveUrine occult blood, BL, TraceUrine occult blood, BL, 1+Urine occult blood, BL, 2+Urine occult blood, BL, 3+Urine occult blood, BL, PositiveUrine occult blood, W4, TraceUrine occult blood, W4, 1+Urine occult blood, W4, 2+Urine occult blood, W4, 3+Urine occult blood, W4, PositiveUrine protein, BL, TraceUrine protein, BL, 1+Urine protein, BL, 2+Urine protein, BL, 3+Urine protein, BL, PositiveUrine protein, W4, TraceUrine protein, W4, 1+Urine protein, W4, 2+Urine protein, W4, 3+Urine protein, W4, Positive
FLOLAN With New Diluent000000000021000010005100020000

[back to top]

Number of Participants With the Reason for the Change Dose of the Thermostable Formulation of FLOLAN

All reasons for FLOLAN dose adjustments after the switch were listed. (NCT02705807)
Timeframe: Up to Week 4

InterventionParticipants (Number)
Adverse eventOther
FLOLAN With New Diluent02

[back to top]

Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils in Blood at Baseline and Week 4

Blood samples were collected for the measurement of percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in blood at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hour (hr) prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionPercentage (Mean)
Basophils BLBasophils W4Eosinophils BLEosinophils W4Lymphocytes BLLymphocytes W4Monocytes BLMonocytes W4Total Neutrophils BLTotal Neutrophils W4
FLOLAN With New Diluent0.610.452.663.2522.8722.375.164.4668.7069.47

[back to top]

Change From Baseline in Body Weight

Body weight was measured at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. Participants with body weight outside and within the clinical concern reference range (<50kg) has been presented. (NCT02705807)
Timeframe: Baseline and Week 4

InterventionParticipants (Number)
> clinical concern range, BL< clinical concern range, BL> clinical concern range, W4< clinical concern range, W4
FLOLAN With New Diluent0606

[back to top]

Change From Baseline in Cardiac Output (CO)

Cardiac output is the volume of blood pumped by the heart per minute. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Baseline and up to Week 4

Interventionliter/minute (Mean)
1hr3hr24hrWeek 4
FLOLAN With New Diluent-0.0700.460-0.0200.408

[back to top]

Change From Baseline in Heart Rate

Heart rate was measured at Baseline, 1 hr, 3 hr, 24 hr, Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Baseline and up to Week 4

InterventionBeats per minute (bpm) (Mean)
1 hr3 hr24 hrWeek 4
FLOLAN With New Diluent1.42.35.14.0

[back to top]

Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) and Mean Right Atrial Pressure (mRAP)

mPAP and mRAP are hemodynamic parameters. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Baseline and up to Week 4

InterventionmmHg (Mean)
mPAP, 1hrmPAP, 3hrmPAP, 24hrmPAP, Week4mRAP, 1hrmRAP, 3hrmRAP, 24hrmRAP, Week4
FLOLAN With New Diluent0.51.5-0.51.9-0.9-0.10.31.5

[back to top]

Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT Pro BNP)

Blood samples were collected at Baseline, 24 hours after the first dose of thermostable formulation of FLOLAN, and Week 4 for measurement of NT pro BNP. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. (NCT02705807)
Timeframe: Baseline and up to Week 4

Interventionnanogram/liter (Mean)
24 hrWeek 4
FLOLAN With New Diluent-1.833.7

[back to top]

Absolute Values of Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Gamma Glutamyltransferase, Lactate Dehydrogenase and Creatine Kinase at Baseline and Week 4

Blood samples were collected for measurement of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Gamma Glutamyltransferase (GGT), Lactate Dehydrogenase (LDH) and Creatine Kinase (CK) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionInternational units per liter (IU/L) (Mean)
ALT, BLALT, W4AST, BLAST, W4ALP, BLALP, W4GGT, BLGGT, W4LDH, BLLDH, W4CK, BLCK, W4
FLOLAN With New Diluent15.919.614.016.4181.0175.222.722.1165.2160.840.844.7

[back to top]

Absolute Values of Albumin and Total Protein at Baseline and Week 4

Blood samples were collected for measurement of albumin and total protein at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionG/L (Mean)
Albumin, BLAlbumin, W4Total protein, BLTotal protein, W4
FLOLAN With New Diluent43.841.168.063.9

[back to top]

Absolute Values of Free Triiodothyronine and Free Thyroxine at Baseline and Week 4

Blood samples were collected for measurement of Free Triiodothyronine (FT3) and Free Thyroxine (FT4) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

Interventionpicomoles per litre (pmol/L) (Mean)
FT3, BLFT3, W4FT4, BLFT4, W4
FLOLAN With New Diluent5.09744.928014.684714.2857

[back to top]

Absolute Values of Hematocrit at Baseline and Week 4

Blood samples were collected for measurement of hematocrit values at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionLiter (L) (Mean)
BLW4
FLOLAN With New Diluent0.39690.3662

[back to top]

Absolute Values of Hemoglobin at Baseline and Week 4

Blood samples were collected for measurement of hemoglobin values at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionGram/Liter (G/L) (Mean)
BLW4
FLOLAN With New Diluent135.5124.1

[back to top]

Absolute Values of Oxygen Saturation

Oxygen saturation was measured by pulse oximetry at Baseline (BL), 1 hr, 3 hr, 24 hr, Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). (NCT02705807)
Timeframe: Baseline and up to Week 4

InterventionPercentage (Mean)
BL1 hr3 hr24 hrWeek 4
FLOLAN With New Diluent97.698.097.697.797.8

[back to top]

Absolute Values of Platelet Count and White Blood Cell Count at Baseline and Week 4

Blood samples were collected for measurement of platelets and white blood cells (WBC) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionGiga/Liter (GI/L) (Mean)
Platelet count, BLPlatelet count, W4WBC count, BLWBC count, W4
FLOLAN With New Diluent181.9153.40.00650.0063

[back to top]

Absolute Values of Red Blood Cell Count at Baseline and Week 4

Blood samples were collected for measurement of red blood cells at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

Interventionterabinary/liter (Ti/L)) (Mean)
BLW4
FLOLAN With New Diluent0.04820.0446

[back to top]

Absolute Values of Thyroid Stimulating Hormone at Baseline and Week 4

Blood samples were collected for measurement of Thyroid Stimulating Hormone (TSH) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

Interventionmilliunits per litre (mU/L) (Mean)
TSH, BLTSH, W4
FLOLAN With New Diluent2.4261.822

[back to top]

Absolute Values of Total and Direct Bilirubin, Creatinine, and Uric Acid at Baseline and Week 4

Blood samples were collected for measurement of total and direct bilirubin, creatinine (CRT), and uric acid (UA) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionMicromoles per liter (Mean)
Total Bilirubin, BLTotal Bilirubin, W4Direct Bilirubin, BLDirect Bilirubin, W4CRT, BLCRT, W4UA, BLUA, W4
FLOLAN With New Diluent9.0638.5500.8551.36858.167250.4764349.1476313.4596

[back to top]

Absolute Values of Urea/Blood Urea Nitrogen, Glucose, Chloride, Sodium, Potassium, Magnesium, Phosphorus (Inorganic), and Calcium at Baseline and Week 4

Blood samples were collected for measurement of urea/Blood Urea Nitrogen (Urea/BUN), glucose, chloride, sodium, potassium, magnesium, phosphorus, inorganic, and calcium at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline') (NCT02705807)
Timeframe: Baseline and Week 4

InterventionMillimoles per litre (mmol/L) (Mean)
Urea/BUN, BLUrea/BUN, W4Glucose, BLGlucose, W4Chloride, BLChloride, W4Sodium, BLSodium, W4Potassium, BLPotassium, W4Magnesium, BLMagnesium, W4Phosphorus, inorganic, BLPhosphorus, inorganic, W4Calcium, BLCalcium, W4
FLOLAN With New Diluent4.67674.46254.99595.7675103.8103.9139.6138.03.613.560.84670.78911.23991.19472.23802.1357

[back to top] [back to top]